Natalizumab therapy for moderate to severe Crohn disease in adolescents.

ABSTRACTObjectives:This study evaluated the safety, tolerability, and efficacy of natalizumab, a humanized monoclonal immunoglobulin-G4 antibody to α4 integrin, in adolescent patients with moderately to severely active Crohn disease (CD).Patients and Methods:In a single-arm study, 38 adolescent pati